Bolt Biotherapeutics (BOLT) Stock Forecast, Price Target & Predictions
BOLT Stock Forecast
Bolt Biotherapeutics stock forecast is as follows: an average price target of $1.00 (represents a 51.86% upside from BOLT’s last price of $0.66) and a rating consensus of 'Hold', based on 13 wall street analysts offering a 1-year stock forecast.
BOLT Price Target
The average price target for Bolt Biotherapeutics (BOLT) is $1.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential 51.86% upside from BOLT's last price of $0.66.
BOLT Analyst Ratings
According to 13 Wall Street analysts, Bolt Biotherapeutics's rating consensus is 'Hold'. The analyst rating breakdown for BOLT stock is 0 'Strong Buy' (0.00%), 5 'Buy' (38.46%), 7 'Hold' (53.85%), 1 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).
Bolt Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Daina Graybosch | Leerink Partners | $1.00 | $1.32 | -24.24% | 51.86% |
The latest Bolt Biotherapeutics stock forecast, released on May 15, 2024 by Daina Graybosch from Leerink Partners, set a price target of $1.00, which represents a -24.24% decrease from the stock price at the time of the forecast ($1.32), and a 51.86% increase from BOLT last price ($0.66).
Bolt Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $1.00 |
| Last Closing Price | $0.66 | $0.66 | $0.66 |
| Upside/Downside | -100.00% | -100.00% | 51.86% |
In the current month, the average price target of Bolt Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bolt Biotherapeutics's last price of $0.66. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 15, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| May 15, 2024 | Leerink Partners | - | Market Perform | Downgrade |
| May 14, 2024 | Guggenheim | - | Neutral | Downgrade |
| May 12, 2023 | Credit Suisse | - | Outperform | Upgrade |
| May 12, 2023 | Raymond James | - | Market Perform | Upgrade |
| May 12, 2023 | Cantor Fitzgerald | - | Overweight | Upgrade |
| May 12, 2023 | Exane BNP Paribas | - | Neutral | Downgrade |
| May 12, 2023 | Wells Fargo | - | Underweight | Downgrade |
| May 12, 2023 | Barclays | - | Equal-Weight | Downgrade |
| May 12, 2023 | BMO Capital | - | Market Perform | Downgrade |
Bolt Biotherapeutics's last stock rating was published by H.C. Wainwright on May 15, 2024. The company Downgrade its BOLT rating from "null" to "Neutral".
Bolt Biotherapeutics Financial Forecast
Bolt Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $2.09M | $2.53M | $1.43M | $1.83M | $1.41M | $2.11M | $1.39M | $813.00K | $508.00K | $752.00K | - | - |
| Avg Forecast | $100.00K | $200.00K | $200.00K | $300.00K | $1.18M | $1.25M | $1.01M | $2.08M | $1.71M | $1.73M | $1.91M | $1.54M | $1.24M | $990.00K | $500.00K | $500.00K | $375.00K | $375.00K | $3.33M | $33.33K |
| High Forecast | $100.00K | $200.00K | $200.00K | $300.00K | $1.18M | $2.15M | $1.03M | $2.08M | $2.16M | $1.73M | $1.91M | $1.54M | $1.24M | $990.00K | $500.00K | $500.00K | $375.00K | $375.00K | $3.33M | $33.33K |
| Low Forecast | $100.00K | $200.00K | $200.00K | $300.00K | $1.18M | $612.99K | $977.70K | $2.07M | $1.30M | $1.73M | $1.91M | $1.54M | $1.24M | $990.00K | $500.00K | $500.00K | $375.00K | $375.00K | $3.33M | $33.33K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.22% | 1.46% | 0.75% | 1.19% | 1.14% | 2.13% | 2.79% | 1.63% | 1.35% | 2.01% | - | - |
Bolt Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $2.08M, with a low forecast of $2.07M, and a high forecast of $2.08M. BOLT's average Quarter revenue forecast represents a -0.67% decrease compared to the company's last Quarter revenue of $2.09M (Dec 23).
Bolt Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-19.77M | $-18.18M | $-19.83M | $-17.95M | $-21.04M | $-21.91M | $-22.65M | $-23.52M | $-26.80M | $-23.09M | $-23.33M | $-30.81M |
| Avg Forecast | $-100.00K | $-200.00K | $-200.00K | $-300.00K | $-1.18M | $-1.25M | $-1.01M | $-2.08M | $-1.71M | $-1.73M | $-1.91M | $-1.54M | $-1.24M | $-990.00K | $-500.00K | $-500.00K | $-375.00K | $-375.00K | $-47.01M | $-33.33K |
| High Forecast | $-100.00K | $-200.00K | $-200.00K | $-300.00K | $-1.18M | $-612.99K | $-977.70K | $-2.07M | $-1.30M | $-1.73M | $-1.91M | $-1.54M | $-1.24M | $-990.00K | $-500.00K | $-500.00K | $-375.00K | $-375.00K | $-37.61M | $-33.33K |
| Low Forecast | $-100.00K | $-200.00K | $-200.00K | $-300.00K | $-1.18M | $-2.15M | $-1.03M | $-2.08M | $-2.16M | $-1.73M | $-1.91M | $-1.54M | $-1.24M | $-990.00K | $-500.00K | $-500.00K | $-375.00K | $-375.00K | $-56.41M | $-33.33K |
| Surprise % | - | - | - | - | - | - | - | - | 11.54% | 10.53% | 10.38% | 11.65% | 17.04% | 22.13% | 45.30% | 47.04% | 71.46% | 61.58% | 0.50% | 924.43% |
undefined analysts predict BOLT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bolt Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Bolt Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-17.90M | $-16.26M | $-18.06M | $-15.54M | $-18.95M | $-21.17M | $-22.27M | $-23.48M | $-27.16M | $-23.39M | $-23.59M | $-31.04M |
| Avg Forecast | $-10.29M | $-10.29M | $-10.29M | $-10.29M | $-11.92M | $-12.96M | $-16.70M | $-19.45M | $-17.92M | $-19.06M | $-18.17M | $-19.06M | $-22.37M | $-21.10M | $-25.07M | $-26.79M | $-30.81M | $-28.60M | $-47.17M | $-24.53M |
| High Forecast | $-10.29M | $-10.29M | $-10.29M | $-10.29M | $-11.92M | $-8.64M | $-16.70M | $-19.45M | $-15.25M | $-19.06M | $-18.17M | $-19.06M | $-22.37M | $-21.10M | $-25.07M | $-26.79M | $-30.81M | $-28.60M | $-37.74M | $-24.53M |
| Low Forecast | $-10.29M | $-10.29M | $-10.29M | $-10.29M | $-11.92M | $-16.56M | $-16.70M | $-19.45M | $-19.83M | $-19.06M | $-18.17M | $-19.06M | $-22.37M | $-21.10M | $-25.07M | $-26.79M | $-30.81M | $-28.60M | $-56.60M | $-24.53M |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 0.85% | 0.99% | 0.82% | 0.85% | 1.00% | 0.89% | 0.88% | 0.88% | 0.82% | 0.50% | 1.27% |
Bolt Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BOLT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Bolt Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $5.53M | $5.76M | $5.62M | $5.62M | $5.61M | $5.49M | $5.53M | $6.30M | $5.10M | $4.94M | $4.05M | $2.06M |
| Avg Forecast | $1.70M | $3.39M | $3.39M | $5.09M | $20.03M | $21.20M | $17.04M | $35.18M | $29.04M | $29.26M | $32.39M | $26.11M | $20.94M | $16.78M | $8.48M | $8.48M | $6.36M | $6.36M | $56.51M | $565.10K |
| High Forecast | $1.70M | $3.39M | $3.39M | $5.09M | $20.03M | $36.37M | $17.51M | $35.18M | $36.55M | $29.26M | $32.39M | $26.11M | $20.94M | $16.78M | $8.48M | $8.48M | $6.36M | $6.36M | $56.51M | $565.10K |
| Low Forecast | $1.70M | $3.39M | $3.39M | $5.09M | $20.03M | $10.39M | $16.58M | $35.18M | $22.11M | $29.26M | $32.39M | $26.11M | $20.94M | $16.78M | $8.48M | $8.48M | $6.36M | $6.36M | $56.51M | $565.10K |
| Surprise % | - | - | - | - | - | - | - | - | 0.19% | 0.20% | 0.17% | 0.22% | 0.27% | 0.33% | 0.65% | 0.74% | 0.80% | 0.78% | 0.07% | 3.64% |
Bolt Biotherapeutics's average Quarter SG&A projection for Mar 24 is $35.18M, based on 2 Wall Street analysts, with a range of $35.18M to $35.18M. The forecast indicates a 535.78% rise compared to BOLT last annual SG&A of $5.53M (Dec 23).
Bolt Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.48 | $-0.41 | $-0.50 | $-0.57 | $-0.60 | $-0.63 | $-0.73 | $-0.63 | $-0.64 | $-0.97 |
| Avg Forecast | $-0.27 | $-0.27 | $-0.27 | $-0.27 | $-0.31 | $-0.34 | $-0.44 | $-0.51 | $-0.47 | $-0.50 | $-0.48 | $-0.50 | $-0.59 | $-0.55 | $-0.66 | $-0.70 | $-0.81 | $-0.75 | $-0.58 | $-0.64 |
| High Forecast | $-0.27 | $-0.27 | $-0.27 | $-0.27 | $-0.31 | $-0.23 | $-0.44 | $-0.51 | $-0.40 | $-0.50 | $-0.48 | $-0.50 | $-0.59 | $-0.55 | $-0.66 | $-0.70 | $-0.81 | $-0.75 | $-0.58 | $-0.64 |
| Low Forecast | $-0.27 | $-0.27 | $-0.27 | $-0.27 | $-0.31 | $-0.43 | $-0.44 | $-0.51 | $-0.52 | $-0.50 | $-0.48 | $-0.50 | $-0.59 | $-0.55 | $-0.66 | $-0.70 | $-0.81 | $-0.75 | $-0.58 | $-0.64 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.01% | 0.82% | 0.85% | 1.03% | 0.91% | 0.90% | 0.90% | 0.84% | 1.09% | 1.51% |
According to undefined Wall Street analysts, Bolt Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BOLT previous annual EPS of $NaN (undefined).
Bolt Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
| CTMX | CytomX Therapeutics | $1.05 | $5.77 | 449.52% | Buy |
| NUVB | Nuvation Bio | $2.30 | $6.75 | 193.48% | Buy |
| TIL | Instil Bio | $28.78 | $78.25 | 171.89% | Hold |
| NXTC | NextCure | $1.33 | $3.00 | 125.56% | Buy |
| ASMB | Assembly Biosciences | $16.89 | $35.50 | 110.18% | Buy |
| ACHL | Achilles Therapeutics | $1.02 | $2.00 | 96.08% | Buy |
| BOLT | Bolt Biotherapeutics | $0.66 | $1.00 | 51.52% | Hold |
BOLT Forecast FAQ
Is Bolt Biotherapeutics a good buy?
No, according to 13 Wall Street analysts, Bolt Biotherapeutics (BOLT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 38.46% of BOLT's total ratings.
What is BOLT's price target?
Bolt Biotherapeutics (BOLT) average price target is $1 with a range of $1 to $1, implying a 51.86% from its last price of $0.658. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bolt Biotherapeutics stock go up soon?
According to Wall Street analysts' prediction for BOLT stock, the company can go up by 51.86% (from the last price of $0.658 to the average price target of $1), up by 51.86% based on the highest stock price target, and up by 51.86% based on the lowest stock price target.
Can Bolt Biotherapeutics stock reach $1?
BOLT's average twelve months analyst stock price target of $1 does not support the claim that Bolt Biotherapeutics can reach $1 in the near future.
What are Bolt Biotherapeutics's analysts' financial forecasts?
Bolt Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5.51M (high $6.44M, low $4.85M), average EBITDA is $-5.513M (high $-4.847M, low $-6.435M), average net income is $-61.024M (high $-56.703M, low $-64.625M), average SG&A $93.46M (high $109.1M, low $82.18M), and average EPS is $-1.601 (high $-1.487, low $-1.695). BOLT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $800K (high $800K, low $800K), average EBITDA is $-800K (high $-800K, low $-800K), average net income is $-41.179M (high $-41.179M, low $-41.179M), average SG&A $13.56M (high $13.56M, low $13.56M), and average EPS is $-1.08 (high $-1.08, low $-1.08).
Did the BOLT's actual financial results beat the analysts' financial forecasts?
Based on Bolt Biotherapeutics's last annual report (Dec 2023), the company's revenue was $7.88M, beating the average analysts forecast of $6.89M by 14.32%. Apple's EBITDA was $-76.196M, beating the average prediction of $-6.889M by 1005.99%. The company's net income was $-69.197M, missing the average estimation of $-74.223M by -6.77%. Apple's SG&A was $22.53M, missing the average forecast of $116.8M by -80.71%. Lastly, the company's EPS was $-0.0018, missing the average prediction of $-1.947 by -99.91%. In terms of the last quarterly report (Dec 2023), Bolt Biotherapeutics's revenue was $2.09M, beating the average analysts' forecast of $1.71M by 21.96%. The company's EBITDA was $-19.766M, beating the average prediction of $-1.713M by 1054.02%. Bolt Biotherapeutics's net income was $-17.903M, missing the average estimation of $-17.92M by -0.10%. The company's SG&A was $5.53M, missing the average forecast of $29.04M by -80.95%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.47 by -99.89%